Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Idiopathic Pulmonary Fibrosis Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety, Tolerability, and Pharmacokinetic Study of NIP292 in Healthy Normal Subjects

NCT04720443
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
NIP292 tablet, NIP292 tablets
Drug
Lead sponsor
The National Institutes of Pharmaceutical R&D Co. Ltd, China
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Jul 21, 2026, 9:22 AM EDT
Terminated Phase 1 Interventional

Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER)

NCT02013700
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs), matched placebo
Biological
Lead sponsor
Joshua M Hare
Other
Eligibility
40 Years to 90 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Jul 21, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

JUNIPER: A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With IPF

NCT03538301
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
ND-L02-s0201 (Low Dose), ND-L02-s0201 (High Dose), Other: Placebo
Drug · Other
Lead sponsor
Nitto Denko Corporation
Industry
Eligibility
40 Years to 80 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
21
States / cities
Tucson, Arizona • Los Angeles, California • Northridge, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2023 · Synced Jul 21, 2026, 9:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Combined PEX, Rituximab and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations

NCT01266317
View directory record Official record
Conditions
IPF
Interventions
Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids
Drug
Lead sponsor
Michael Donahoe
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Jul 21, 2026, 9:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Randomized, Crossover, Multi-Dose Pharmacokinetics of EXCL-100 Pirfenidone-Sustained Release Tablet and Esbriet in Healthy Volunteers

NCT05428150
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Esbriet 267 MG Oral Capsule, EXCL-100, 600 MG Oral Tablet
Drug
Lead sponsor
Excalibur Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Jul 21, 2026, 9:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pulmonary Fibrosis Contact Registry

NCT01935726
View directory record Official record
Conditions
Pulmonary Fibrosis of Any Cause, Primary Supporters/Caretakers of Patients With Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 100 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Jul 21, 2026, 9:22 AM EDT
Completed Not applicable Interventional

IPF mHealth Exercise Study

NCT04838275
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
12-week mHealth home exercise prescription
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
40 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Jul 21, 2026, 9:22 AM EDT
Terminated Phase 2 Interventional

A Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPF

NCT03864328
View directory record Official record
Conditions
Persistent Cough in IPF, Chronic Cough, IPF
Interventions
RVT-1601, Placebo
Drug
Lead sponsor
Respivant Sciences GmbH
Industry
Eligibility
40 Years to 89 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
28
States / cities
Birmingham, Alabama • Sacramento, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Jul 21, 2026, 9:22 AM EDT
Completed No phase listed Observational

Impact of Pre-transplant Anti-fibrotic Therapy for IPF Upon Lung Transplant Outcomes

NCT04316780
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Retrospective observational study- no intervention to occur.
Other
Lead sponsor
Steward St. Elizabeth's Medical Center of Boston, Inc.
Other
Eligibility
Not listed
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
8
States / cities
Iowa City, Iowa • Boston, Massachusetts • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Jul 21, 2026, 9:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Blood Levels of GSK3915393 Administered to Healthy Participants of Chinese, Japanese and European Ancestry and to Assess Effects of GSK3915393 on Nintedanib

NCT06625489
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Part A: Placebo, Nintedanib, GSK3915393
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Cypress, California • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Jul 21, 2026, 9:22 AM EDT
Completed Early Phase 1 Interventional

Safety and Efficacy of Venetoclax in Idiopathic Pulmonary Fibrosis

NCT05976217
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Venetoclax
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Jul 21, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension

NCT00705133
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
Interventions
Treprostinil
Drug
Lead sponsor
Rajan Saggar
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Jul 21, 2026, 9:22 AM EDT
Completed Phase 3 Interventional

Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

NCT04708782
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Interventions
Placebo, Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer
Drug · Device
Lead sponsor
United Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
90
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 21, 2026, 9:22 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Peripheral Blood Biomarkers in Idiopathic Interstitial Pneumonias

NCT01151527
View directory record Official record
Conditions
Idiopathic Interstitial Pneumonias
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
2
States / cities
Denver, Colorado • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 8, 2015 · Synced Jul 21, 2026, 9:22 AM EDT
Terminated Phase 3 Interventional Results available

ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

NCT00879229
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
Interventions
Ambrisentan, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
35 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
51
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Davis, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Jul 21, 2026, 9:22 AM EDT
Recruiting Phase 3 Interventional

Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)

NCT07284602
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
Deupirfenidone, Pirfenidone (PFD)
Drug
Lead sponsor
PureTech
Industry
Eligibility
40 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
9
States / cities
Palm Spring, California • Redding, California • North Dartmouth, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 21, 2026, 9:22 AM EDT
Completed Phase 3 Interventional

Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial

NCT04300920
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
N-acetyl cysteine, Placebo
Drug
Lead sponsor
Fernando J Martinez
Other
Eligibility
40 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
25
States / cities
Tucson, Arizona • Los Angeles, California • Stanford, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jul 21, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT01872689
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Lebrikizumab, Pirfenidone, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years and older
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
54
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Jul 21, 2026, 9:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Kinetics and Repeatability of 18F-BMS-986327

NCT04069143
View directory record Official record
Conditions
Healthy Participants, Idiopathic Pulmonary Fibrosis (IPF)
Interventions
18F-BMS-986327
Diagnostic Test
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Jul 21, 2026, 9:22 AM EDT
Terminated Phase 3 Interventional Results available

A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care

NCT03733444
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
GLPG1690, Placebo
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
40 Years and older
Enrollment
781 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Jul 21, 2026, 9:22 AM EDT
Withdrawn No phase listed Observational

Evaluation of Patients With Idiopathic Pulmonary Fibrosis (IPF) Through an IPF Registry

NCT00212511
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Jul 21, 2026, 9:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Assessment of Lung Movement With Computed Tomography (CT)

NCT03068091
View directory record Official record
Conditions
Interstitial Lung Disease
Interventions
Chest CT, Pulmonary Function Testing
Device · Diagnostic Test
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Jul 21, 2026, 9:22 AM EDT
Terminated Phase 2 Interventional

A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

NCT05785624
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Systemic Sclerosis With Lung Involvement
Interventions
Vixarelimab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jul 21, 2026, 9:22 AM EDT
Recruiting No phase listed Observational

The Role of Quantitative CT and Radiomic Biomarkers for Precision Medicine in Pulmonary Fibrosis

NCT06323876
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
HRCT, Blood Draw
Diagnostic Test
Lead sponsor
University of Virginia
Other
Eligibility
40 Years to 101 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Jul 21, 2026, 9:22 AM EDT